amivantamab
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
FDA Approves Janssen's Rybrevant, Chemo in Frontline NSCLC With EGFR Exon 20 Insertions
The agency also converted Rybrevant's accelerated approval to a full approval in previously treated NSCLC harboring these mutations.
J&J Seeking Frontline Rybrevant-Lazertinib FDA Approval in EGFR-Mutated NSCLC
The application contains data from the Phase III MARIPOSA trial in which the dual anti-EGFR regimen improved outcomes versus AstraZeneca's Tagrisso.
Janssen Seeking FDA Approval for Rybrevant-Chemo in EGFR-Mutated NSCLC After Prior Tagrisso Therapy
The firm filed a supplemental biologics licensing application seeking approval for the combination based on data from the Phase III MARIPOSA-2 clinical trial.
Experts at ESMO said the MARIPOSA studies support Rybrevant combinations as potential options for NSCLC, but survival data and patient stratification are needed.